Page 6 - Oncology Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncology development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncology Development Today - Breaking & Trending Today

Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors

In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs. 8.5 months with high-dose octreotide LAR in patients with newly diagnosed grade 2. ....

United States , Baja California , Richard Jarvis , Satoshi Sugimoto , Marlena Abdinoor , Sloan Simpson , Michael Meo , Isabella Zinck , Imke Kappes , Simron Singh , Parag Mahanti , Julie Masow , Samir Shah , Jeff Legos , Jonathan Graham , Nicole Zinsli Somm , American Society Of Clinical Oncology , University Of Toronto , Sunnybrook Health Sciences Centre , Global Head Of Oncology Development At Novartis , Odette Cancer Centre , Exchange Commission , Elsevier Inc , Clinical Oncology , Associate Professor , Susan Leslie Clinic ,

Novartis Lutathera® Phase III trial results

Novartis Lutathera® significantly reduced the risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors.In the. ....

Jeff Legos , Novartis Lutathera , Global Head Of Oncology Development At Novartis , Global Head , Oncology Development ,

Astellas Provides Update on Zolbetuximab Biologics License Application in U.S.

TOKYO, Jan. 8, 2024 /PRNewswire/ Astellas Pharma Inc. today announced the U.S. Food and Drug Administration issued a complete response letter on January 4, 2024, regarding the Biologics License. ....

Moitreyee Chatterjee Kishore , Naoki Okamura , Oncology Development , Astellas Pharma Inc , Prnewswire Astellas Pharma Inc , Drug Administration , Biologics License Application , Prescription Drug User Fee Act , Senior Vice President , Immuno Oncology Development , Priority Review , Zolbetuximab Biologics License , Focus Area Approach ,

FDA Issues CRL to Zolbetuximab for Advanced HER2–, CLDN18.2+ Gastric/GEJ Cancer

The FDA has issued a complete response letter regarding the biologics license application seeking the approval of zolbetuximab for the treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are Claudin18.2 positive ....

Astellas Pharma , Moitreyee Chatterjee Kishore , Oncology Development , Prescription Drug User Fee Act , Immuno Oncology Development , Bangy J , Gastric Cancer , Complete Response Letter , Gastroesophageal Junction Adenocarcinoma , Locally Advanced Unresectable Or Metastatic Her2 Negative , Claudin18 2 ,

Astellas Provides Update on Zolbetuximab Biologics License Application in U.S.

Astellas Provides Update on Zolbetuximab Biologics License Application in U.S.
webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.

Moitreyee Chatterjee Kishore , Zolbetuximab Biologics , Naoki Okamura , Drug Administration , Astellas Pharma Inc , Oncology Development , Astellas Provides Update , Zolbetuximab Biologics License Application , Biologics License Application , Prescription Drug User Fee Act , Senior Vice President , Immuno Oncology Development , Priority Review , Zolbetuximab Biologics License , Focus Area Approach , Press Release Image ,